ERBB2 and non-small cell lung carcinoma: In xenograft models derived from patients with EGFR or HER2 exon 20 mutant NSCLC and genetically engineered NSCLC mouse models in vitro, poziotinib showed stronger activity than approved EGFR-TKIs [62].